Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma-Reference-Cited by-同舟云学术

Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma

Author:

Beaumont Jennifer L.¹,Salsman John M.²³,Diaz Jose⁴,Deen Keith C.⁵,McCann Lauren⁵,Powles Thomas⁶,Hackshaw Michelle D.⁷,Motzer Robert J.⁸,Cella David¹⁹

Affiliation:

1. Department of Medical Social Sciences; Northwestern University Feinberg School of Medicine; Chicago Illinois

2. Department of Social Sciences and Health Policy; Wake Forest School of Medicine; Winston-Salem North Carolina

3. Comprehensive Cancer Center at Wake Forest Baptist; Winston-Salem North Carolina

4. Novartis Pharma AG; Basel Switzerland

5. GlaxoSmithKline; Collegeville Pennsylvania

6. Barts Cancer Institute; London United Kingdom

7. Novartis Pharma Services AG; Basel Switzerland

8. Memorial Sloan Kettering Cancer Center; New York New York

9. Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Chicago Illinois

Funder

GlaxoSmithKline

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

Reference12 articles.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献